Nakamura S, Ishiyama M, Kosaka J, Mutoh J, Umemura N, Harase C
Department of Internal Medicine, Gifu Red Cross Hospital, Japan.
Endocrinol Jpn. 1991 Jun;38(3):303-8. doi: 10.1507/endocrj1954.38.303.
Urinary N-acetyl-beta-D-glucosaminidase (NAG) activity was measured longitudinally in 12 patients with Graves' disease, 5 patients with subacute thyroiditis, and 1 patient with silent thyroiditis, and compared with that of 36 normal controls. The patients with Graves' disease and subacute thyroiditis were treated with anti-thyroid drug (methimazole or propylthiouracil) and prednisolone, respectively. On the other hand, no treatment was given to the patient with silent thyroiditis. Since two patients with Graves' disease clearly showed transient deterioration of the thyroid function during the treatment period, data from these two patients were separately investigated. Urinary levels of NAG in the remaining ten patients with Graves' disease before, 1, 3, 6 and 12 months after the treatment were 15.59 +/- 7.93 (SD), 8.96 +/- 6.82, 4.39 +/- 2.33, 3.46 +/- 2.24, and 3.63 +/- 2.38 U/g.creatinine (g.Cr.), respectively. Those obtained before, 1 and 3 months after the treatment were significantly higher than those of the controls (2.85 +/- 1.12 U/g.Cr.). Free thyroid hormone levels became normal or low 3 months after the treatment. The two Graves' patients mentioned above showed a transient increase in urinary NAG with concomitant changes in free thyroid hormone levels. Urinary NAG levels in the patients with subacute thyroiditis before, 2, 4, and 6 weeks after the treatment were 16.56 +/- 10.97, 6.76 +/- 2.79, 3.14 +/- 0.48 and 3.70 +/- 1.44 U/g.Cr., respectively. Those obtained before and 2 weeks after the treatment were significantly higher than those of the controls. Free thyroid hormones were normal 2 weeks after therapy. Urinary NAG in the patient with silent thyroiditis was 9.60 U/g.Cr. on the first visit and gradually decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
对12例格雷夫斯病患者、5例亚急性甲状腺炎患者和1例寂静性甲状腺炎患者的尿N - 乙酰 - β - D - 氨基葡萄糖苷酶（NAG）活性进行了纵向测定，并与36名正常对照者的进行比较。格雷夫斯病患者和亚急性甲状腺炎患者分别接受抗甲状腺药物（甲巯咪唑或丙硫氧嘧啶）和泼尼松龙治疗。另一方面，寂静性甲状腺炎患者未接受治疗。由于2例格雷夫斯病患者在治疗期间甲状腺功能明显出现短暂恶化，对这2例患者的数据进行了单独研究。其余10例格雷夫斯病患者治疗前、治疗后1个月、3个月、6个月和12个月的尿NAG水平分别为15.59±7.93（标准差）、8.96±6.82、4.39±2.33、3.46±2.24和3.63±2.38 U/g肌酐（g.Cr.）。治疗前、治疗后1个月和3个月的尿NAG水平显著高于对照组（2.85±1.12 U/g.Cr.）。治疗3个月后游离甲状腺激素水平恢复正常或降低。上述2例格雷夫斯病患者尿NAG短暂升高，同时游离甲状腺激素水平发生变化。亚急性甲状腺炎患者治疗前、治疗后2周、4周和6周的尿NAG水平分别为16.56±10.97、6.76±2.79、3.14±0.48和3.70±1.44 U/g.Cr.。治疗前和治疗后2周的尿NAG水平显著高于对照组。治疗2周后游离甲状腺激素恢复正常。寂静性甲状腺炎患者初诊时尿NAG为9.60 U/g.Cr.，随后逐渐下降。（摘要截取自250词）
